Financials data is unavailable for this security.
View more
Year on year Serina Therapeutics Inc had net income fall 41.49% from a loss of 10.46m to a larger loss of 14.80m despite a 317.65% increase in revenues from 34.00k to 142.00k.
| Gross margin | 49.72% |
|---|---|
| Net profit margin | -10,438.55% |
| Operating margin | -6,720.67% |
| Return on assets | -162.58% |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Serina Therapeutics Inc fell by 300.00k. Cash Flow from Financing totalled 17.50m or 12,323.94% of revenues. In addition the company used 7.80m for operations while cash used for investing totalled 10.00m.
| Cash flow per share | -4.18 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -1.86 |
|---|---|
| Tangible book value per share | -1.92 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.7059 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
